I thought that selective modulators of PPAR gamma phosphorylation would be the next stage in development (see this work from Merck for example): http://molpharm.aspetjournals.org/content/early/2012/04/11/mol.111.076679.full.pdf But Daiichi dumped its agent recently after reviewing its clinical studies results and I cannot see others that look viable.